Postoperative Chemotherapy in Resected Gastric Cancer: Results of a Single Center Experience

References

• Barchielli A, Amorosi A, Balzi D, Crocetti E, Nesi G. Long-term prognosis of gastric cancer in a European country: a pop-ulation-based study in Florence (Italy). Eur J Cancer 2001; 37: 1674–80
   PubMed Web of Science ®Google Scholar
• Ferlay J, Autier P, Boniol M, Heanue M, Colombet M, Boyle P. Estimates of the cancer incidence and mortality in Eu-rope in 2006. Ann Oncol. 2007; 18: 581–92
   PubMed Web of Science ®Google Scholar
• Jemal A, Siegel R, Ward E et al. Cancer Statistics, 2007. CA Cancer J Clin 57: 43-66, 2007
   Google Scholar
• American Joint Committee on Cancer. Stomach. 5th ed. Philadelphia, Lippincott-Raven; 1997: 71–76
   Google Scholar
• De Vita F, Giuliani F, Galizia G et al. Neo-adjuvant and ad-juvant chemotherapy of gastric cancer. Ann Oncol 18 (suppl 6): 120-123, 2007
   Google Scholar
• Wu AW, Xu GW, Wang HY, Tang JL. Neoadjuvant chemotherapy versus none for resectable gastric cancer. Cochrane Database Syst Rev 2: CD005047, 2007
   PubMedGoogle Scholar
• Van Cutsem E, Dicato M, Arber N et al. The neo-adjuvant, surgical and adjuvant treatment of gastric adenocarcinoma. Cur-rent expert opinion derived from the Seventh World Congress on Gastrointestinal Cancer, Barcelona, 2005. Ann Oncol. 2006; 17 Suppl 6: vi13–8
   Google Scholar
• Hermans J, Bonenkamp JJ, Boon MC et al. Adjuvant ther-apy after curative resection for gastric cancer: meta-analysis of randomised trials. J Clin Oncol 1993; 11 (8): 1441–7
   PubMed Web of Science ®Google Scholar
• Earle CC, Maroun JA. Adjuvant chemotherapy after cura-tive resection for gastric cancer in non-Asian patients: revisiting a meta-analysis of randomised trials. Eur J Cancer 1999; 35 (7): 1059–64
   PubMed Web of Science ®Google Scholar
• Mari E, Floriani I Tinazzi A et al. Efficacy of adjuvant chemotherapy after curative resection for gastric cancer: a meta-analysis of published randomised trials. Ann Oncol 2000; 11: 837–43
   Google Scholar
• Panzini I, Gianni L, Fattori PP et al. Adjuvant chemother-apy in gastric cancer: a meta-analysis of randomized trials and a comparison with previous meta-analyses. Tumori 2002; 88: 21–7
   Google Scholar
• Janunger KG, Hafstrom L, Glimelius B. Chemotherapy in gastric cancer: a review and updated meta-analysis. Eur J Surg 2002; 168: 597–608.
   PubMedGoogle Scholar
• Wagner PK, Ramaswamy A, Rushoff J, Shmitt-Moormann P, Rothmund M. Lymph nodes counts in the upper abdomen: anatomical basis for lymphadenectomy in gastric cancer. Br J Surg 1991; 78 (7): 825–7
   PubMed Web of Science ®Google Scholar
• Wilke H, Preusser P, Stahl M et al: Etoposide, folinic acid, and 5-fluorouracil in carboplatin-pretreated patients with ad-vanced gastric cancer. Cancer Chemother Pharmacol 29: 83–84, 1991
   PubMed Web of Science ®Google Scholar
• Cocconi G, Bella M, Zironi S et al. Fluorouracil, doxoru-bicin, and mitomycin combination versus PELF chemotherapy in advanced gastric cancer: a prospective randomized trial of the Italian Oncology Group for Clinical Research. J Clin Oncol. 1994 12 (12): 2687–9
   Google Scholar
• Neri B, De Leonardis V, Romano S et al. Adjuvant chemotherapy after gastric resection in node positive gastric can-cer patients: a multicentre randomised study. Br J Cancer 1996; 73: 549–52
   Google Scholar
• Miller AB, Hoogstraten B, Staquet M, Winkler A. Report-ing results of cancer treatment. Cancer 1981; 47: 207–214
   PubMed Web of Science ®Google Scholar
• Cirera L, Balil A, Batiste-Alentorn E et al. Randomized clinical trial of adjuvant mitomycin plus tegafur in patients with re-sected stage III gastric cancer. J Clin Oncol 1999; 17: 3810–5
   PubMed Web of Science ®Google Scholar
• Nitti D, Wits J, Dos Santos JG et al. Randomized phase III trials of adjuvant FAMTX or FEMTX compared with surgery alone in resected gastric cancer. A combined analysis of the EORTC GI Group and the ICCG. Ann Oncol. 2006; 17: 262–9
   Google Scholar
• Bouché O, Ychou M, Burtin P et al Adjuvant chemother-apy with 5-fluorouracil and cisplatin compared with surgery alone for gastric cancer: 7-year results of the FFCD randomized phase III trial (8801). Ann Oncol 2005 16: 1488-97
   Google Scholar
• Bajetta E, Buzzoni R, Mariani L et al. Adjuvant chemother-apy in gastric cancer: 5-year results of a randomised study by the Italian Trials in Medical Oncology (ITMO) Group. Ann Oncol. 2002; 13 (2): 299–307
   Google Scholar
• Cascinu S, Labianca R, Barone C, Santoro A, Carnaghi C, Cassano A. Adjuvant treatment of high-risk, radically resected gastric cancer patients with 5-fluorouracil, leucovorin, cisplatin, and epidoxorubicin in a randomized controlled trial. J Natl Can-cer Inst. 2007; 99: 601–7
   PubMedGoogle Scholar
• Mac Donald JS, Smalley S, Benedetti J et al. Chemother-apy after surgery compared with surgery alone for adenocarci-noma of the stomach or gastroesophageal junction. N Engl J Med 2001; 345: 725–30
   Google Scholar
• Cunningham D, Allum WH, Stenning SP et al. Perioper-ative chemotherapy versus surgery alone for resectable gastroe-sophageal cancer. N Engl J Med. 2006 ; 355 (1): 11–20
   Google Scholar
• Van Cutsem E, Moiseyenko VM, Tjulandin Setal.; V325 Study Group. Phase III study of docetaxel and cisplatin plus fluo-rouracil compared with cisplatin and fluorouracil as first-line ther-apy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol. 2006; 24 (31): 4991–7
   PubMed Web of Science ®Google Scholar
• Cunningham D, Starling N, Rao S et al.; Upper Gastroin-testinal Clinical Studies Group of the National Cancer Research Institute of the United Kingdom. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med. 2008; 358 (1): 36–46
   PubMed Web of Science ®Google Scholar
• Bouché O, Raoul JL, Bonnetain F et al.; Fédération Fran-cophone de Cancérologie Digestive Group. Randomized multi-center phase II trial of a biweekly regimen of fluorouracil and leucovorin (LV5FU2), LV5FU2 plus cisplatin, or LV5FU2 plus irinotecan in patients with previously untreated metastatic gas-tric cancer: a Federation Francophone de Cancerologie Diges-tive Group Study—FFCD 9803. J Clin Oncol. 2004; 22 (21): 4319–28
   PubMed Web of Science ®Google Scholar
• MacDonald JS. Gastric cancer - new therapeutic options. New Engl J. Med 2006; 355: 76–77
   PubMed Web of Science ®Google Scholar